This is a summary of the European public assessment report (EPAR). It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the studies performed, to reach its recommendations on how to use the medicine. If you need more information about your medical condition or your treatment, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist. If you want more information on the basis for the CHMP recommendations, read the scientific discussion (also part of the EPAR).
Therapeutic Indication
### Therapeutic indication Treatment of essential hypertension. This fixed-dose combination is indicated in adult patients whose blood pressure is not adequately controlled on irbesartan or hydrochlorothiazide alone.
Therapeutic Area (MeSH)
N/AATC Code
C09DA04
ATC Item
irbesartan and diuretics
Pharmacotherapeutic Group
Agents acting on the renin-angiotensin system
Active Substance (Summary)
N/AINN / Common Names
N/AEMA Name
Irbesartan/Hydrochlorothiazide Teva
Medicine Name
Irbesartan/Hydrochlorothiazide Teva
Aliases
N/ANo risk management plan link.
